Who are Intra-Arterial TNK and Albumin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Reteplase 10 U, Tenecteplase thrombolysis, TNKase, reteplase 10+10 U, Oral lumbrokinase DLBS1033, thrombolysis therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intra-arterial-tnk-and-albumin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Intra-Arterial TNK and Albumin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intra-Arterial TNK and Albumin (Intra-Arterial TNK and Albumin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombolytic agent with albumin carrier. Area: Cardiovascular; Neurology.

phase 3 Thrombolytic agent with albumin carrier Fibrin; plasminogen Cardiovascular; Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Intra-Arterial TNK and Albumin (Intra-Arterial TNK and Albumin) — Tianjin Huanhu Hospital. Intra-arterial TNK (tenecteplase) and albumin work together to deliver thrombolytic therapy directly to occluded arteries while albumin may enhance drug delivery and reduce systemic toxicity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intra-Arterial TNK and Albumin TARGET	Intra-Arterial TNK and Albumin	Tianjin Huanhu Hospital	phase 3	Thrombolytic agent with albumin carrier	Fibrin; plasminogen
Reteplase 10 U	Reteplase 10 U	The University of Texas Health Science Center, Houston	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Fibrin; plasminogen
Tenecteplase thrombolysis	Tenecteplase thrombolysis	Xuanwu Hospital, Beijing	marketed	Fibrinolytic agent / Thrombolytic	Fibrin; Plasminogen
TNKase	TNKase	Cedars-Sinai Medical Center	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Fibrin; plasminogen
reteplase 10+10 U	reteplase 10+10 U	Sahlgrenska University Hospital	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA) analog	Fibrin; plasminogen
Oral lumbrokinase DLBS1033	Oral lumbrokinase DLBS1033	Universitas Sebelas Maret	marketed	Fibrinolytic enzyme	Fibrin; plasminogen activation pathway
thrombolysis therapy	thrombolysis therapy	Leiden University Medical Center	phase 3	Thrombolytic agent	Fibrin; plasminogen/plasmin pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombolytic agent with albumin carrier class)

Tianjin Huanhu Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intra-Arterial TNK and Albumin — Competitive Intelligence Brief. https://druglandscape.com/ci/intra-arterial-tnk-and-albumin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab